Literature DB >> 3057682

Circadian time dependence of murine tolerance for carboplatin.

N A Boughattas1, F Lévi, B Hecquet, G Lemaigre, A Roulon, C Fournier, A Reinberg.   

Abstract

A large amplitude circadian rhythm in murine tolerance for the anticancer agent, carboplatin (cyclobutane dicarboxylatoplatinum II, CBDCA) was demonstrated. Two studies were performed in a total of 266 male B6D2F1 mice standardized by LD 12:12. In the first experiment CBDCA (80 mg/kg/day) was administered intravenously (iv) daily for three consecutive days at all six circadian stages (3, 7, 11, 15, 19, or 23 hr after light onset, HALO). CBDCA dosing at 15 HALO resulted in 58% long-term survivors as compared to 0% after treatment at 3 or 23 HALO (chi 2 = 28; p less than 0.001). In the second experiment, CBDCA (72 or 80 mg/kg/day X 3 days, iv) was administered at any of three circadian stages (0, 8, or 16 HALO). Mice were killed, blood was collected, and seven tissues were obtained 5 and 10 days after the first dose, in order to determine serum urea and creatinine concentrations, leukocyte and red blood cell counts, and to evaluate histologic lesions. No renal toxicity was encountered. Bone marrow and colon mucosa were the major target tissues of CBDCA in these dosages and schedules. CBDCA dosing at 16 HALO was least toxic to the bone marrow as assessed by peripheral leukocyte count and histologic score (p from ANOVA less than 0.05). Histologically assessed lesions of the colon mucosa were less severe after CBDCA dosing at 16 HALO as compared to those at 8 HALO, and significantly so for the lowest dosage tested (p approximately 0.05). Uptake of CBDCA 24 hr after the third dose ranged from 23 micrograms/g of dry tissue in the colon to 7 micrograms/g in the duodenum. Mean tissue concentrations increased between Day 4 and Day 10 for the liver and spleen, and remained similar for the kidney. No consistent circadian dependence was found with regard to Day 4 mean Pt uptake in different tissues, whereas the lowest Day 10 Pt concentrations corresponded to CBDCA dosing at 16 HALO for all tissues investigated. Toxicity did not appear to be directly related to the total platinum concentration in these tissues.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3057682     DOI: 10.1016/0041-008x(88)90083-x

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  2 in total

1.  Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma.

Authors:  Galina Kireeva; Ekaterina Gubareva; Mikhail Maydin; Vladislav Osetnik; Stepan Kruglov; Andrey Panchenko; Anastasia Dorofeeva; Margarita Tyndyk; Elena Fedoros; Vladimir Anisimov
Journal:  Onco Targets Ther       Date:  2021-05-24       Impact factor: 4.147

2.  The prevention of cisplatin-induced renal dysfunction by hydroxyl-containing dithiocarbamates.

Authors:  L V Reznik; E M Myazina; E I Shakchmatova; S P Gambaryan; V K Brovtsyn; Y V Natochin; M M Jones
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.